<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693637</url>
  </required_header>
  <id_info>
    <org_study_id>P-105-202</org_study_id>
    <nct_id>NCT04693637</nct_id>
  </id_info>
  <brief_title>Study of Viralym-M (ALVR105) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant</brief_title>
  <official_title>Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Viralym-M Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlloVir</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlloVir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Viralym-M (ALVR105) to placebo for the prevention of&#xD;
      six viruses of interest in high-risk patients post-Allogeneic Hematopoietic Cell Transplant&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare patients treated with Viralym-M to patients treated with placebo on the proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end-organ disease</measure>
    <time_frame>Through Week 14</time_frame>
    <description>The proportion of patients on Viralym-M vs on Placebo with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare patients treated with Viralym-M to patients treated with placebo on time to onset of AdV, BKV, CMV, EBV, HHV-6, and/or JCV</measure>
    <time_frame>Through Week 14</time_frame>
    <description>Time to onset of viruses of interest, Viralym-M compared to Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare patients treated with Viralym-M to patients treated with placebo on area under the curve (AUC) for cumulative viral load for AdV, BKV, CMV, EBV, HHV-6, and JCV</measure>
    <time_frame>Through Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare patients treated with Viralym-M to patients treated with placebo on the proportion of patients with clearance of AdV, BKV, CMV, EBV, HHV-6, and/or JCV viremia in allogenic HCT patients</measure>
    <time_frame>Through Week 26</time_frame>
    <description>The proportion of patients on Viralym-M vs on Placebo with clearance of AdV, BKV, CMV, EBV, HHV-6, and/or JCV viremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare patients treated with Viralym-M to patients treated with placebo on the proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end-organ diseases</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Proportion of patients on Viralym-M vs on Placebo with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end-organ diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare patients treated with Viralym-M to patients treated with placebo on duration of hospitalization related to AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection or disease</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare patients treated with Viralym-M to patients treated with placebo on proportion of patients with AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease-related mortality</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Proportion of patients with AdV, BKV, CMV, EBV, HHV-6, and/or JCV disease-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT-BMT (Functional Assessment of Cancer Therapy - Bone Marrow Transplantation) score will be reported numerically and compared between baseline and end of treatment for both treatment groups</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Comparison of Viralym-M to Placebo on patient-reported quality of life measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L will be reported as an index between baseline and end of treatment for both treatment groups</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Comparison of Viralym-M to Placebo on age-appropriate patient-reported quality of life measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D-Y will be reported as an index between baseline and end of treatment for both treatment groups</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Comparison of Viralym-M to Placebo on age-appropriate patient-reported quality of life measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-Y will be reported as an index between baseline and end of treatment for both treatment groups</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Comparison of Viralym-M to Placebo on age-appropriate patient-reported quality of life measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence and severity of post-HCT safety AEs in patients treated with Viralym-M compared with placebo</measure>
    <time_frame>Through Week 26</time_frame>
    <description>Incidence and severity of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>BK Virus Infection</condition>
  <condition>JC Virus Infection</condition>
  <condition>Epstein-Barr Virus Infections</condition>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Adenovirus Infection</condition>
  <condition>Human Herpes Virus-6 Infection</condition>
  <arm_group>
    <arm_group_label>Viralym-M (OL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Viremia Cohort &amp; Viremia Cohort, Arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viralym-M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No Viremia Cohort &amp; Viremia Cohort, Arm 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viralym-M Cells</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Viralym-M</arm_group_label>
    <arm_group_label>Viralym-M (OL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (visually identical to Viralym-M)</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have had a high-risk Allogeneic Hematopoietic Transplant within 15 to 42&#xD;
             days of first dose in study&#xD;
&#xD;
          -  Either no evidence of viral infection or viremia, or asymptomatic, viral infection&#xD;
             with 3 or fewer viruses of interest at time of screening&#xD;
&#xD;
          -  At least 1 identified, suitably matched Viralym-M cell line for infusion is available&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in the&#xD;
             protocol.&#xD;
&#xD;
          -  Contraceptive use by men and women consistent with local regulations regarding the&#xD;
             methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Not pregnant or breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of AdV, BKV, CMV, HHV-6, and/or JCV end-organ disease within 6 months&#xD;
             prior to treatment assignment&#xD;
&#xD;
          -  Evidence of active Grade &gt;2 graft versus host disease (GVHD)&#xD;
&#xD;
          -  Presence of non-minor uncontrolled or progressive bacterial or fungal infections (ie,&#xD;
             evidence of bacteremia, fungemia, disseminated)&#xD;
&#xD;
          -  Ongoing therapy with high-dose systemic corticosteroids&#xD;
&#xD;
          -  Pregnant or lactating or planning to become pregnant&#xD;
&#xD;
          -  Weight &lt;30 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dee Rodriguez</last_name>
    <phone>833-409-2281</phone>
    <email>ClinicalTrials@allovir.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens-Ayers T, Milano F, Delaney C, Sorror ML, Sandmaier BM, Nichols G, Zerr DM, Jerome KR, Schiffer JT, Boeckh M. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017 Apr 20;129(16):2316-2325. doi: 10.1182/blood-2016-10-748426. Epub 2017 Feb 16.</citation>
    <PMID>28209721</PMID>
  </reference>
  <reference>
    <citation>Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7.</citation>
    <PMID>28783452</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

